Controlled cannabis vaporizer administration: Blood and plasma cannabinoids with and without alcohol

Clinical Chemistry

Volumn 61, Issue 6, 2015, Pages 850-869

  Hartman, Rebecca L ^a,b   Brown, Timothy L ^c   Milavetz, Gary ^c   Spurgin, Andrew ^c   Gorelick, David A ^d   Gaffney, Gary ^e   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; GLUCURONIDE; TETRAHYDROCANNABINOL; 11-HYDROXY-DELTA(9)-TETRAHYDROCANNABINOL; CANNABINOID; DRONABINOL; MEDICAL CANNABIS;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANNABIS SMOKING; CANNABIS VAPORIZER; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; VAPORIZATION; VAPORIZER; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; NEBULIZER; ORAL DRUG ADMINISTRATION; YOUNG ADULT;

CANNABIS;

ADMINISTRATION, ORAL; ADULT; CANNABINOIDS; DRONABINOL; ETHANOL; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MEDICAL MARIJUANA; NEBULIZERS AND VAPORIZERS; YOUNG ADULT;

EID: 84930536123     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2015.238287     Document Type: Article

References (40)

1. 23 Legal medical marijuana states and DC: laws, fees, and possession limits. ProCon.org. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881 (Accessed December 2014).
2. Lacey J, Brainard K, Snitow S. Drug per se laws: a review of their use in states. National Highway Traffic Safety Administration; 2010. DOT HS 811 317. http://www.nhtsa.gov/staticfiles/nti/impaired-driving/pdf/811317.pdf (Accessed April 2015).
3. Johnson MB, Kelley-Baker T, Voas RB, Lacey JH. The prevalence of cannabis-involved driving in California. Drug Alcohol Depend 2012;123:105-9.
4. The legalization of marijuana in Colorado: the impact. Rocky Mountain High Intensity Drug Trafficking Area. 2013;1:1-66.
5. Hartman RL, Huestis MA. Cannabis effects on driving skills. Clin Chem 2013;59:478-92.
6. Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem 2013;59:519-26.
7. Grotenhermen F, Leson G, Berghaus G, Drummer OH, Krüger HP, Longo M, et al. Developing limits for driving under cannabis. Addiction 2007;102:1910-7.
8. Legrand SA, Isalberti C, Van der Linden T, Bernhoft IM, Hels T, Simonsen KW, et al. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test Anal 2013;5:156-65.
9. Baggio S, Deline S, Studer J, Mohler-Kuo M, Daeppen JB, Gmel G. Routes of administration of cannabis used for nonmedical purposes and associations with patterns of drug use. J Adolesc Health 2014;54:235-40.
10. Zuurman L, Roy C, Schoemaker R, Hazekamp A, den Hartigh J, Bender J, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 2008;22:707-16.
11. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007;82:572-8.
12. Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised cannabis sativa. Inhal Toxicol 2009;21:1108-12.
13. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J 2007;4:11.
14. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:657-90.
15. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011;57:1406-14.
16. Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 2014;60:631-43.
17. Nadulski T, Sporkert F, Schnelle M, Stadelmann AM, Roser P, Schefter T, Pragst F. Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract. J Anal Toxicol 2005;29:782-9.
18. Adamson SJ, Sellman JD. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev 2003;22:309-15.
19. Sobell LC, Sobell MB. Alcohol consumption measures. In: Allen JP, Wilson VB, editors. Assessing alcohol problems: a guide for clinicians and researchers. 2nd Ed. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism, NIH; 2003:75-99.
20. Scheidweiler KB, Schwope DM, Karschner EL, Desrosiers NA, Gorelick DA, Huestis MA. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis. Clin Chem 2013;59:1108-17.
21. Schwope D, Scheidweiler K, Huestis M. Direct quantification of cannabinoids and cannabinoid glucuronides in whole blood by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401:1273-83.
22. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006;95:1308-17.
23. Perez-Reyes M. Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. In: Chiang CN, Hawks RL, editors. Research findings on smoking of abused substances. Rockville (MD): NIDA; 1990. p 42-62. NIDA research monograph 99.
24. Azorlosa JL, Greenwald MK, Stitzer ML. Marijuana smoking: effects of varying puff volume and breath-hold duration. J Pharmacol Exp Ther 1995;272:560-9.
25. Hazekamp A. The Volcano® Medic cannabis vaporizer: optimal temperature for single-dose administration of 100 mg cannabis or 10 mg Dronabinol. Lieden, the Netherlands: LabAssistent Phytochemical Services; 2010. http://www.vapormed.com/volcano-medic-vaporizer-en-study-research.php (Accessed 25 March 2011).
26. Downey LA, King R, Papafotiou K, Swann P, Ogden E, Boorman M, Stough C. The effects of cannabis and alcohol on simulated driving: influences of dose and experience. Accid Anal Prev 2013;50:879-86.
27. Bosker WM, Theunissen EL, Conen S, Kuypers KP, Jeffery WK, Walls HC, et al. A placebo-controlled study to assess standardized field sobriety tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. Psychopharmacology (Berl) 2012;223:439-46.
28. Toennes S, Schneider K, Kauert G, Wunder C, Moeller M, Theunissen E, Ramaekers J. Influence of ethanol on cannabinoid pharmacokinetic parameters in chronic users. Anal Bioanal Chem 2011;400:145-52.
29. Ramaekers J, Theunissen E, de Brouwer M, Toennes S, Moeller M, Kauert G. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology 2011;214:391-401.
30. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: effects on psychomotor performance. Alcohol Clin Exp Res 1988;12:268-76.
31. Lukas SE, Orozco S. Ethanol increases plasma delta-9-tetrahydrocannabinol (THC) levels and subjective effects after marihuana smoking in human volunteers. Drug Alcohol Depend 2001;64:143-9.
32. Linnoila M, Mattila MJ, Kitchell BS. Drug interactions with alcohol. Drugs 1979;18:299-311.
33. Riff DP, Jain AC, Doyle JT. Acute hemodynamic effects of ethanol on normal human volunteers. Am Heart J 1969;78:592-7.
34. Fabritius M, Augsburger M, Chtioui H, Favrat B, Giroud C. Fitness to drive and cannabis: validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers. Forensic Sci Int 2014;242:1-8.
35. Karschner EL, Darwin WD, Goodwin RS, Wright S, Huestis MA. Plasma cannabinoid pharmacokinetics following controlled oral Delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem 2011;57:66-75.
36. Karschner EL, Schwope DM, Schwilke EW, Goodwin RS, Kelly DL, Gorelick DA, Huestis MA. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC. Drug Alcohol Depend 2012;125:313-9.
37. Biecheler MB, Peytavin JF, Facy F, Martineau H. SAM survey on 'Drugs and fatal accidents': search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. Traffic Inj Prev 2008;9:11-21.
38. Szaflarski JP, Martina Bebin E. Cannabis, cannabidiol, and epilepsy: from receptors to clinical response. Epilepsy Behav 2014;41C:277-82.
39. Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R. Antipsychotic effect of cannabidiol. J Clin Psychiatry 1995;56:485-6.
40. Ramaekers J, Kauert G, Theunissen E, Toennes S, Moeller M. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J Psychopharmacol 2009;23:266-77.